HIV/AIDS: Prevention drug trial disappoints PDF Print E-mail

 A three-country study has been halted after daily doses of the antiretroviral (ARV) Truvada, used as a pre-exposure prophylaxis (PrEP), failed to prevent HIV infection in the women participating. 

Read full article here.